Evidence map›Paper›PMID 37037195›Full record

ArticleBrain pathology (Zurich, Switzerland)2023

TDP-43 and tau concurrence in the entorhinal subfields in primary age-related tauopathy and preclinical Alzheimer's disease.

Josué Llamas-Rodríguez, Jan Oltmer, Michael Marshall, Samantha Champion, Matthew P Frosch, Jean C Augustinack

Open access · goldAbstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Riboregulation: a non-canonical tau function.Molecular neurodegeneration · 2026
    Review
  3. Review
  4. TDP-43: [GU]-ardian of the transcriptome.Molecular neurodegeneration · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Primary age-related tauopathy.Acta neuropathologica · 2025
    Review
  9. Review
  10. Review
  11. Entorhinal vessel density correlates with phosphorylated tau and TDP-43 pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Josué Llamas-RodríguezDepartment of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, Massachusetts, USA.ORCID 0000-0002-5532-7786
Jan OltmerDepartment of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, Massachusetts, USA.
Michael MarshallDepartment of Neuropathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Samantha ChampionDepartment of Neuropathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Matthew P FroschDepartment of Neuropathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Jean C AugustinackDepartment of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, Massachusetts, USA.ORCID 0000-0002-3129-6671
Massachusetts General Hospital · US

Funding

Building a pathology-validated neuroimaging tool for Alzheimer's DiseaseR01AG057672 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI AUGUSTINACK, JEAN · 2018 to 2022
$2.4M
Identifying microscopic vasculature within entorhinal cortex in healthy aging and its proximity to pathology profiles in Alzheimer's diseaseRF1AG082223 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI AUGUSTINACK, JEAN · 2023 to 2023
$2.1M
Establishing cellular-validated standards for parcellating hippocampal subfields in aging and Alzheimer's diseaseRF1AG072056 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI AUGUSTINACK, JEAN · 2021 to 2021
$1.7M
Establishing cellular-validated standards for parcellating hippocampal subfields in aging and Alzheimer's diseaseR01AG072056 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI AUGUSTINACK, JEAN · 2024 to 2025
$1.1M
NIA NIH HHS R01 AG057672NIA NIH HHS R01 AG072056NIA NIH HHS RF1 AG072056NIA NIH HHS RF1 AG082223
6 · The paper itself

Abstract

Phosphorylated tau (p-tau) pathology correlates strongly with cognitive decline and is a pathological hallmark of Alzheimer's Disease (AD). In recent years, phosphorylated transactive response DNA-binding protein (pTDP-43) has emerged as a common comorbidity, found in up to 70% of all AD cases (Josephs et al., Acta Neuropathol, 131(4), 571-585; Josephs, Whitwell, et al., Acta Neuropathol, 127(6), 811-824). Current staging schemes for pTDP-43 in AD and primary age-related tauopathy (PART) track its progression throughout the brain, but the distribution of pTDP-43 within the entorhinal cortex (EC) at the earliest stages has not been studied. Moreover, the exact nature of p-tau and pTDP-43 co-localization is debated. We investigated the selective vulnerability of the entorhinal subfields to phosphorylated pTDP-43 pathology in preclinical AD and PART postmortem tissue. Within the EC, posterior-lateral subfields showed the highest semi-quantitative pTDP-43 density scores, while the anterior-medial subfields had the lowest. On the rostrocaudal axis, pTDP-43 scores were higher posteriorly than anteriorly (p < 0.010), peaking at the posterior-most level (p < 0.050). Further, we showed the relationship between pTDP-43 and p-tau in these regions at pathology-positive but clinically silent stages. P-tau and pTDP-43 presented a similar pattern of affected subregions (p < 0.0001) but differed in density magnitude (p < 0.0001). P-tau burden was consistently higher than pTDP-43 at every anterior-posterior level and in most EC subfields. These findings highlight pTDP-43 burden heterogeneity within the EC and the posterior-lateral subfields as the most vulnerable regions within stage II of the current pTDP-43 staging schemes for AD and PART. The EC is a point of convergence for p-tau and pTDP-43 and identifying its most vulnerable neuronal populations will prove key for early diagnosis and disease intervention.

Indexed as

Alzheimer DiseaseTauopathiesBrainDNA-Binding ProteinsEntorhinal CortexHumanstau ProteinsDNA-Binding Proteinstau Proteinsagingentorhinal corteximmunohistochemistryneurofibrillary tanglesneuronal cytoplasmic inclusionspathology concurrence

Identifiers

PMID37037195
PMCPMC10307525
OpenAlexW4363678043

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.